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Abstract 
Background: Data about paclitaxel-eluting balloon (PCB) angioplasty to treat drug-eluting 
stents (DES) in-stent restenosis (ISR) were mainly collected in selected patient populations in 
the setting of randomized trials. The main goal of this prospective registry was to confirm the 
positive findings of these studies in an unselected population in clinical practice. 
Methods: Consecutive patients with DES-ISR treated by PCB angioplasty were recruited in 
this prospective real-world registry. The primary endpoint was clinically driven target-lesion 
revascularization (TLR) at 9 months. Secondary endpoints included acute technical success, 
in-hospital outcomes, 9-month major adverse cardiac events (MACE) a composite of death, 
myocardial infarction (MI) and TLR and the occurrence of target vessel revascularization. 
Results: A total of 206 patients (67.7±10.2 years, 80.6% male, 41.3% diabetics) with 210 
lesions were recruited. Unstable coronary artery disease was present in 55.3% of patients. The 
time from DES implantation to DES-ISR was 3.0±2.4 years. Quantitative analyses revealed 
that patterns of treated DES-ISR were focal in 55.7% and diffuse in 44.3%. The reference 
diameter was 2.76 ±0.64 mm. The 9-month follow-up rate was 90.8% (187/206). At 9 
months, the TLR rate was 7.0% (13/187) whereas the rates for MACE, MI and cardiac death 
were 10.7% (20/187), 4.8% (9/187) and 2.1% (4/187) respectively. Results were consistent in 
patients with paclitaxel and non-paclitaxel-eluting stents (PES) ISR. 
Conclusion: This large prospective registry demonstrated acceptable rates of TLR and 
MACE at 9 months after treatment of DES-ISR by PCB angioplasty. PCB angioplasty was 
equally effective in patients with PES-ISR and non PES-ISR. 
Key words: drug-eluting stent in-stent restenosis, paclitaxel-coated balloon, target lesion 
revascularization 
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Introduction 
The introduction of drug-eluting stents (DES), through the dramatically decreased 
incidence of in-stent restenosis (ISR) it yielded, is considered a revolution in the field of 
percutaneous coronary intervention (PCI)1. The further-improved safety profile of new-
generation DES led to their unrestricted use in increasingly complex patients and lesions2,3 so 
that latest European guidelines4 state that DES should be considered by default in all clinical 
conditions and lesion subsets. However, DES have not eliminated the ISR issue as a recent 
angiographic study shown that these new-generation devices are still plagued by a 12% rate of 
angiographic ISR5. 
 Paclitaxel-coated balloon (PCB) were initially studied in bare-metal stent (BMS) ISR 
against plain old balloon angioplasty (POBA)6-9 or paclitaxel-eluting stent (PES)10, since it 
appeared very attractive to locally deliver a drug without the introduction of additional stent 
layers. These studies showed an early and sustained benefit of PCB over POBA on 
angiographic and clinical outcomes whereas only a trend towards better clinical results was 
achieved against PES despite significantly improved angiographic findings with PCB. There 
are increasing data regarding treatment of DES-ISR by PCB angioplasty either compared to 
POBA11,12, PES13 or both techniques14. These studies demonstrated that late lumen loss 
(LLL), diameter stenosis (%) and major adverse cardiac events (MACE) were consistently 
and significantly lower in patients treated by PCB than in patients treated by POBA11,12. 
Moreover, PCB angioplasty matched the angiographic and clinical results of repeat stenting 
with PES13,14. These data recently led the European Society of Cardiology to give a class IA 
recommendation for the use of PCB in BMS and DES-ISR4. In this setting, the main goal of 
this observational study was to confirm these positive findings in an unselected French patient 
population under routine use. 
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Methods 
Objectives 
The aim of the GARO (Groupe des Angioplasticiens de la Région Ouest) registry was 
to evaluate the safety and efficacy of PCB angioplasty to treat DES-ISR in native coronary 
arteries. This was a non-randomized, open-label, single arm, observational registry conducted 
in 13 French centers (see list in Appendix). The protocol was approved by the French national 
ethics committee as part of the parent ‘All-Comers Registry’ which also included other 
indications beside DES-ISR. All patients gave written informed consent. Data were captured 
using an established electronic case report form with built-in plausibility checks previously 
proved useful and efficient in related observational PCB studies15,16. The two coordinating 
investigators (MB,JB) were responsible to contact co-investigators whenever the e-CRF 
plausibility checks indicated discrepancies. 
Patients 
All consecutive patients >18 years old with DES-ISR, treated by PCB angioplasty 
were enrolled in this registry. All Mehran types of ISR17 in native coronary arteries with 
reference vessel diameters between ≤ 2.5 and ≤ 3.5 mm and ≤ 22 mm in length were eligible. 
ISR had to reduce the reference vessel diameter either by ≥70% or ≥50% with documented 
ischemia corresponding to the target lesion. Major exclusion criteria were: cardiogenic shock, 
Killip class III heart failure, pregnant/lactating women, severe valvular heart disease, patients 
with a life-expectancy < 5 years and patients with contraindications to dual-antiplatelet 
therapy or known hypersensitivity to acetylsalicylic acid, clopidogrel, paclitaxel, or heparin. 
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Endpoints and definitions 
The primary endpoint was clinically driven target lesion revascularization at 9 months 
(TLR) as a composite of re-PCI and coronary artery bypass grafting (CABG). Secondary 
endpoints included the procedural success rate, definite acute/subacute vessel thrombosis rates 
as defined by the ARC criteria18. Moreover, major adverse cardiac events (MACE), defined as 
the composite of TLR, death of cardiac or unknown origin and myocardial infarction (MI), 
were also documented. Myocardial infarction was diagnosed with corresponding ECG 
changes and/or cardiac enzyme elevations according to each institution’s routine diagnostic 
algorithms. 
Procedure 
Patients received 500 mg of aspirin before the intervention or were receiving long-
term treatment. A clopidogrel loading dose of 300-600 mg was administered. Heparin (50-
100UI/kg) was administered upon insertion of the sheath. Intracoronary Nitrates (0.2 mg) 
were administered 2 minutes before baseline and final reference angiography performed in 
two near-orthogonal views. The paclitaxel-coated (3μg/mm²) PTCA catheter based on the 
Paccocath® Technology (SeQuent® Please, B.Braun Melsungen AG) was used accordingly 
to previously published guidelines19. Especially, special attention was given to proper 
predilation of the target lesion and PCB was not used unless residual diameter stenosis was ≤ 
30% after balloon predilation.  A 60s PCB inflation at a minimum of 10 bar was 
recommended unless not tolerated by the patient (hypotension and/or severe ventricular 
arrhythmia due to ischemia). Additional stents were implanted in case of significant recoil, 
residual stenosis or dissections after PCB therapy. Lesion length and vessel reference 
diameter were assessed using online quantitative coronary angiography or visual estimation. 
Dual-antiplatelet therapy was recommended for at least 9 months after the procedure. 
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Quantitative Coronary Angiography 
Angiographic data were routinely collected pre- and post-procedure with the use of 
identical projections and analyses. Quantitative analysis of the coronary angiographic images 
was done by 2 independent operators in an independent angiographic core laboratory. A 
difference of ±3% of the relative stenosis between the two operators was deemed acceptable. 
If the discrepancy exceeded this value, a third operator decided upon the result of the 
assessment. In case of insufficient quality of the angiogram, the patient was rejected. The 
CAAS II research system (Quantcor QCA, Pie Medical Imaging, Maastricht, The 
Netherlands) was used for automated contour detection and quantification.   
Statistical analysis 
Continuous variables are expressed as mean±SD. Normality was tested using 
Kolmogorov-Smirnov test. Continuous variables were compared using unpaired t-test or 
Mann-Whitney U-test as appropriate. Categorical variables are presented as counts and 
percentages and were compared with the use of Fisher’s exact or χ2 test, as appropriate. Time-
to-event data are shown as Kaplan-Meier curves and were compared using the log-rank test. 
Kaplan-Meier curves reports end?points that were censored at the time of first event or at 9 
months, whichever occurred first. All reported p-value are 2-sided and a p-value <0.05 was 
considered significant. Analyses were done with SAS version 9.2 (SAS Institute Cary, NC 
USA) and SPSS version 20.0 (IBM, Munich, Germany). Subgroup analyses were planned for 
DES-ISR subgroups consisting of PES-ISR and non-PES-ISR due to potential differences in 
clinical outcomes. 
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Results 
Patients 
From February 2011 to April 2013, a total of 206 consecutive patients (mean age: 
67.7±10.2 years; male sex: 80.6%) were included in the present study. Diabetes mellitus was 
present in 85 patients (41.3%), 143 (69.4%) had hypertension, 156 (75.7%) had 
hyperlipidemia and 97 (47.1%) were current smokers. Thirty four patients (16.5%) presented 
with MI and a total of 114 patients (55.3%) had unstable coronary artery disease at 
presentation. The mean time from DES implantation to DES-ISR was 3.0±2.4 years. Table 1 
summarizes baseline clinical characteristics of the study population and provides a 
comparison between patients with a PES-ISR (n=42) and a non PES-ISR (n=164). Both 
groups were comparable at the exception of a higher rate of unstable angina in the PES-ISR 
group (43.3% vs. 21.4%, p=0.009). 
Baseline angiographic characteristics (Table 2) 
The majority of patients had single-vessel disease (56.8%) with a target lesion located 
in the left anterior descending artery in the left anterior descending coronary artery in 37.6%, 
the left circumflex coronary artery in 27.6% and the right coronary artery in 29.0%. The most 
represented target stent types were PES (21.2%), sirolimus-eluting stent (SES, 38.4%) and 
new-generation everolimus-eluting stent (EES, 29.1%). Diffuse ISR pattern was present in 
44.3% of patients.  
Quantitative coronary angiographic analysis and procedural characteristics 
The mean lesion length and reference vessel diameter were 12.59±8.87mm and 
2.77±0.78mm respectively (Table 3). The mean residual stenosis diameter was 15.6±12.5% 
post-index procedure (Table 3). Diameter stenosis was smaller in the PES-ISR group 
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(57.5±17.2% vs. 67.2±16.4%, p=0.002). However, this difference was not observed after the 
intervention (14.6±11.1% vs. 15.9±12.8%, p=0.575). There were also no post-procedural 
differences between groups in terms of reference vessel diameter (p=0.446) and MLD 
(p=0.262). 
 
The mean PCB length and diameter were 19.5±4.9mm and 3.0±0.36mm respectively. 
For treatment of 210 lesions, 227 PCB were used (1.07 PCB per lesion).The mean inflation 
pressure was 12.6±3.7 bar. After PCB therapy, dissections were documented in 3 lesions 
(1.4%) and 6 patients (2.9%) necessitated additional stenting. Procedural characteristics are 
summarized in Table 4. Procedural success of the PCB interventions was reported for 207 
lesions (98.6%) with a borderline significant difference (p=0.046) between the PES-ISR and 
non-PES-ISR groups (Table 4). 
In-hospital and accumulated 9-months clinical events 
There were no differences between the PES-ISR and the non PES-ISR groups during 
hospitalization (Table 5). Overall there was only one cardiac death and one TLR up to the 
point of discharge. Complete follow-up (by telephone: 79.7% or by hospital visit: 20.3%) was 
achieved in 187 patients (90.8%) at a mean of 8.9±0.84 months. The primary endpoint of TLR 
occurred in 13 patients (7.0%) whereas 10.7% of patients suffered a MACE. 9-month rates of 
MI and cardiac death were 4.8% and 2.1% respectively (Figure 1, Table 5).  
There was no difference between the PES-ISR and the non PES-ISR groups in the 9-
month rates of TLR (3.6% vs. 7.0%, p=0.314), MACE (7.2% vs. 9.2%, p=0.738), MI (4.8% 
vs. 4.4%, p=0.772), cardiac death (4.8% vs. 1.4%, p=0.791) as assessed by Kaplan-Meier 
method (Figure 2). Regarding TLR rates, these results were consistent across various 
subgroups. However, patients with a delay between DES implantation and DES-ISR < 12 
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months presented a clear trend towards higher rate of MACE (Figure 3). Although, treatment 
of new-generation EES-ISR resulted in higher absolute 9-months rates of TLR (9.7% vs. 
4.7%) and MACE (15.3% vs. 6.8%), these differences did not reach statistical significance.  
Discussion 
 The main finding of the present study is that PCB angioplasty to treat DES-ISR 
achieved acceptably low rates of TLR and MACE at 9 months in a French unselected patient 
population which is in agreement with previously conducted DES-ISR trials.  
  DES-ISR and BMS-ISR share some common mechanisms such as stent 
underexpansion, stent fracture, stent malapposition, and non-uniform strut distribution but 
DES-ISR also presents specific stimuli of neointimal thickening like localized 
hypersensitivity, non-uniform drug deposition, polymers and drug resistance20,21. This may 
explain why treatment of DES-ISR remains highly challenging. Indeed, a recent multicenter 
retrospective analysis of 392 patients with 481 DES-ISR lesions, which were treated with 
repeat DES stenting in 66% of cases, showed rates of recurrent restenosis ranging from 29.0 
to 65.6% depending on the initial pattern of DES-ISR21. Some authors9,22 suggested that DES-
ISR identifies a high-risk group of patients in which the best available antirestenotic therapy 
to date has failed and PCB angioplasty in this setting, like repeat DES stenting,  has shown 
worse results than in the treatment of BMS-ISR9,12. The results of the present study showing 
higher absolute rates of TLR and MACE after treatment of new-generation EES-ISR support 
this idea of a very challenging group of patients exhibiting signs of resistance to our current 
“gold-standard”. 
 Previous studies investigating the efficacy and safety of PCB angioplasty to treat DES-
ISR reported rates of TLR ranging from 2.9% at 6 months9 to 22.1% at 12 months14 and rates 
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of MACE ranging from 6.6%9 to 23.5%14 at the same time points (Table 6). Thus, the clinical 
outcomes of the present study are in agreement with previously published trials9,11-14.  Post-
procedural diameter stenosis (Table 6) was 15.6±12.5% in our series which agrees well with 
the findings in the ISAR DESIRE 314 (18.5±8.3%) and the PEPCAD DES12 (12.6%±6.2%) 
trials. Even lower procedural diameter stenoses were reported by Xu et al.13 (10.5%±7.2%) 
whereas Habara and coworkers documented the highest remaining degree of stenosis 
(25.7%±7.2%). These discrepancies seems attributable to lower post-procedural MLD in 
studies by Habara et al.9,11 which highlights the adamant importance of a proper pre-dilation 
of the lesion before using a PCB with regard to angiographic outcomes. These procedural 
results does not necessarily relate to clinical outcomes (Table 6) however they greatly 
influence the conclusion of studies using an angiographic measure at follow-up as their 
primary end-point. Intermodality studies comparing PCB angioplasty to repeat DES stenting 
might especially be prone to this bias as repeat stenting usually results in higher post-
procedural MLD13,14,23. Moreover, the number of stent layers may introduce additional bias. 
Rittger et al12 reported that 53.6% of the ISR lesions treated in their patient population had at 
least 2 metal layers the latest being a DES which may explain the relatively high late lumen 
loss in the PCB and POBA groups (0.43± 0.61 mm vs. 1.03± 0.77 mm, p<0.001). Our belief 
is that a proper pre-dilation is of adamant importance in the setting of DES-ISR.  Cutting and 
especially the more flexible and deliverable scoring balloons may be particularly attractive as 
they allow device anchoring in the lesion, deep incision of neointimal tissue and prevent 
“watermelon seeding” effect which might be responsible for edge dissection and unplanned 
stent implantation. Whether these devices provide better results in the treatment of DES-ISR 
is currently the subject of ongoing clinical trials (21). 
 Our finding that PCB angioplasty results in similar clinical outcomes after treatment of 
PES-ISR and non PES-ISR is in line with the conclusion of the ISAR-DESIRE 2 study24. In 
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this trial, 450 patients with 483 SES-ISR lesions were randomized to repeat DES stenting 
with either a SES or a PES. No differences were seen between the two strategies with regard 
to angiographic or clinical outcomes. On the contrary, the RIBS III (Restenosis Intra-Stent: 
Balloon Angioplasty Versus Drug-Eluting Stent) trial, a prospective multicenter registry 
including 363 patients with DES-ISR, demonstrated, after adjustment using propensity score 
analyses, a significant reduction of the composite of cardiac death, MI and TLR (hazard ratio: 
0.56, 95% CI: 0.33 to 0.96, p=0.038) with the use of a switch strategy25. If overall data about 
the switch strategy remain inconclusive, an interesting point in the RIBS III trial is the 
suggestion of a superiority of second-generation DES over first-generation DES. Indeed, so 
far, studies and meta-analyses support non-inferiority of PCB angioplasty against first-
generation DES10,13,14,26,27 but little is known about the comparative effectiveness of PCB and 
new-generation DES in DES-ISR. A recent study by Almalla et al.28 compared PCB 
angioplasty to EES implantation in an DES-ISR study population using a historic control arm 
and showed significantly lower TLR and MACE rates in the PCB group. Contrarily, in the 
setting of BMS-ISR, the RIBS V (Restenosis Intra-stent: Drug-eluting Balloon vs. 
Everolimus-eluting Stent) trial23, which recently provided the first randomized comparison of 
PCB angioplasty with second-generation EES in 189 patients, demonstrated improved 
angiographic results (LLL, diameter stenosis) after EES. However, binary restenosis rates 
were low and similar in both groups (4.7% vs. 9.5%, p =0.22) and these better angiographic 
results did not translate into improved clinical outcomes. Therefore, additional data are 
needed to define the respective roles of PCB angioplasty and EES implantation in the 
treatment of DES-ISR. 
 The time course between DES implantation and ISR seems to be an important factor to 
consider when addressing the issue of DES-ISR. We showed a higher rate of MACE in 
patients with a delay between DES implantation and DES-ISR < 12 months. The shorter the 
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time frame from DES implantation to DES-ISR is, the less likely ISR is to be caused by 
neointimal hyperplasia whereas mechanical factors probably play a crucial role. It has also 
been shown that early ISR presentation was correlated to diffuse ISR patterns which may 
explain the worse results we observed in the sub-group of patients with a short delay between 
DES implantation and ISR as the morphological pattern of DES-ISR is an important predictor 
of clinical outcomes, especially TLR20. 
By definition a study limitation of all-comers registries is a less stringent control of 
data collection. Moreover, source data monitoring was only conducted whenever 
discrepancies were detected by the electronic data capture system. As a consequence, some 
under-reporting may have occurred in the present study. Owing to the evaluation of PCB 
angioplasty in routine clinical practice, we did not provide an angiographic follow-up and the 
database did not include information about intracoronary imaging techniques as their use to 
identify underlying mechanical factors was left to the discretion of the operator in this real-
life setting. However, rates of 20% and even 42% of stent under-expansion were reported 
respectively in the setting of BMS-ISR (29) and DES-ISR (30). Thus, the crucial importance 
of identifying these mechanical issues cannot be enough emphasized to reach better results 
when dealing with DES-ISR. 
Conclusion 
PCB angioplasty to treat DES-ISR delivered an acceptably low 9-month TLR rate in a French 
unselected patient population which is in agreement with previously conducted DES-ISR 
trials. No difference was seen between PES-ISR and non-PES-ISR patients treated with PCB-
angioplasty. Cardiovascular and lesion related risk factors were not predictors of MACE. 
However, if DES-ISR occurred within 12 months the risk of MACE at 9 months was higher 
in these early DES-ISR patients after PCB angioplasty. 
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Figure legends 
Figure 1-Rates of major adverse cardiac events, target lesion revascularization, myocardial 
infarction and cardiac death according to the type of drug-eluting stent in-stent restenosis.  
ISR= in-stent restenosis; MACE= major adverse cardiac events; MI= myocardial infarction; 
PES= paclitaxel-eluting stent; TLR= target lesion revascularization. 
Figure 2-Kaplan Meier time-to-event curves showing cumulative rates of major adverse 
cardiac events, target lesion revascularization, myocardial infarction and cardiac death with 
comparison of cumulative rates according to the type of drug-eluting stent in-stent restenosis.  
ISR= in-stent restenosis; MACE= major adverse cardiac events; MI= myocardial infarction; 
PES= paclitaxel-eluting stent; TLR= target lesion revascularization. 
Figure 3- Adjusted odds-ratio and corresponding 95% confidence intervals for major adverse 
cardiac events. 
CI= confidence interval; DES= drug-eluting stents; ISR= in-stent restenosis; MACE= major 
adverse cardiac events; OR=odds-ratio PES= paclitaxel-eluting stent. 
Reference categories are: non PES-ISR; DES-ISR delay < 1 year; focal ISR, no diabetes 
mellitus, no hypertension, no hyperlipidemia. 
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Appendix 
List of participating centers: Centre Hospitalier Universitaire d’Angers; Centre Hospitalier 
d’Avignon ; Centre Hospitalier de Bourges; Centre Hospitalier de Chartres ; Centre 
Hospitalier de Colmar ; Centre Hospitalier Universitaire Nord de Marseille ; Centre 
Hospitalier Universitaire de Montpellier ; Polyclinique les Fleurs Ollioules ; Centre 
Hospitalier de Pau ; Centre Hospitalier Universitaire de Rennes ; Centre Hospitalier 
Universitaire de Rouen ; Clinique Saint-Hilaire Rouen ; Centre Hospitalier Universitaire de 
Toulouse. 
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Table 1 Baseline demographic characteristics. 
 
All patients 
(n=206) 
PES-ISR group 
(n=42) 
Non PES-ISR 
group (n=164) 
p-value 
Age, yrs 67.7±10.2 66.9±11.4 67.9±9.9 0.586 
Male 166 (80.6) 36 (85.7) 130 (79.3) 0.341 
Diabete mellitus 85 (41.3) 14 (33.3) 71 (43.3) 0.242 
Hypertension 143 (69.4) 27 (64.3) 116 (70.7) 0.419 
Hyperlipidemia 156 (75.7) 35 (83.3) 121 (73.8) 0.198 
Current smoker 97 (47.1) 22 (52.4) 75 (45.7) 0.441 
End stage renal disease 11 (5.3) 1 (2.4) 10 (6.1) 0.339 
Stress test available 65 (31.6) 11 (26.2) 54 (32.9) 0.402 
Positive stress test 63 (96.9) 11 (100) 52 (96.3) 0.517 
Unstable angina 80 (38.8) 71 (43.3) 9 (21.4) 0.009 
Non-STEMI 26 (12.6) 7 (16.7) 19 (11.6) 0.376 
STEMI 8 (3.9) 0 (0.0) 8 (4.9) 0.144 
ISR delay, yrs 3.0±2.4 3.2±2.2 3.0±2.4 0.558 
Values are mean ± SD or n (%). 
ISR= in-stent restenosis; PES= paclitaxel-eluting stent; STEMI= ST-elevation myocardial infarction. 
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Table 2 Baseline angiographic characteristics. 
 
All 
patients/lesions 
(n=206/210) 
PES-ISR 
group 
(n=42/43) 
Non PES-ISR 
group (n=164/167) p-value 
Diagnostic coronary findings    0.524 
    Single-vessel disease 117 (56.8) 27 (64.3) 90 (54.9) 
    Two-vessel disease 53 (25.7) 8 (19.0) 45 (27.4) 
    Three-vessel disease 36 (17.5) 7 (16.7) 29 (17.7) 
Target vessel    0.318 
    LAD 79 (37.6) 18 (41.9) 61 (36.5) 
    LCX 58 (27.6) 13 (30.9) 45 (26.9) 
    RCA 61 (29.0) 12 (27.2) 49 (29.3) 
    Other 12 (5.7) 0 (0) 12 (7.2) 
Target stenti    <0.001 
    PES 43 (21.2) 43 (100) 0 
    SES 78 (38.4) 0 (0) 78 (48.8) 
    ZES 12 (5.9) 0 (0) 12 (7.5) 
    EES 59 (29.1) 0 (0) 59 (36.9) 
    BES 6 (3.0) 0 (0) 6 (3.7) 
    Other 5 (2.5) 0 (0) 5 (3.1) 
ISR classificationii    0.706 
    Articulation/Gap 2 (1.0) 1 (2.4) 1 (0.6) 
    Focal margin 21 (10.2) 4 (9.8) 17 (10.4) 
    Focal body 79 (38.5) 14 (34.1) 65 (39.6) 
    Multifocal 10 (4.9) 1 (2.4) 9 (5.5) 
    Diffuse 71 (34.6) 18 (43.9) 53 (32.3) 
    Proliferative 15 (7.3) 2 (4.9) 13 (7.9) 
    Occlusive 7 (3.4) 1 (2.4) 6 (3.7) 
Diffuse ISR pattern 93 (44.3) 21(48.8) 72 (43.1) 0.606 
Target lesion characteristics     
    TIMI flow 0 or 1 16 (7.6) 3 (7.0) 13 (7.8) 1.000 
    B2-C lesion 72 (34.3) 18 (41.9) 54 (32.3) 0.281 
Values are mean ± SD or n (%) 
BES= biolimus-eluting stent; EES= everolimus-eluting stent; LAD= left anterior descending artery; 
LCX= left circumflex; RCA= right coronary artery; SES= sirolimus-eluting stent; TIMI= thrombolysis 
in myocardial infarction; ZES= zotarolimus-eluting stent. Other abbreviations as in table 1. 
iPercentage of lesions with data available about target stent type (n=203). 
iiPercentage of lesions with data available about ISR classification (n=205). 
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Table 3 Quantitative coronary analysis*. 
 All lesions 
(n=163/210) 
PES-ISR group 
(n=36/43) 
Non PES-ISR 
group 
(n=127/167) 
p-value 
Before index procedure     
   Lesion length, mm 12.59±8.87 15.02±12.61 11.99±7.4 0.07 
   Reference vessel diameter, mm 2.77±0.78 2.74±0.55 2.78±0.84 0.033 
   Minimal lumen diameter, mm 0.98±0.47 1.13±0.40 0.92±0.48 0.021 
   Diameter stenosis, % 65.1±17.0 57.5±17.2 67.2±16.4 0.002 
Post-index procedure     
   Reference vessel diameter, mm 2.78±0.52 2.72±0.45 2.80±0.54 0.446 
   Minimal lumen diameter, mm 2.37±0.55 2.22±0.57 2.39±0.54 0.262 
   Diameter stenosis, % 15.6±12.5 14.6±11.1 15.9±12.8 0.575 
*Based on angiographic data from patients with sufficient quality for analysis. 
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Table 4 Procedural and device characteristics. 
 
All lesions 
(n=210) 
PES-ISR 
group (n=43) 
Non PES-ISR 
group (n=167) p-value 
Balloon pre-dilation 195 (92.9) 41 (95.3) 154 (92.2) 0.477 
Number of PCB used 227 45 182 - 
Paclitaxel-coated balloon     
    Diameter, mm 3.0±0.36 2.97±0.42 3.0±0.34 0.305 
    Length, mm 19.5±4.9 20.3±5.8 19.3±4.6 0.816 
    Inflation pressure, bar 12.6±3.7 13.4±4.8 12.4±3.4 0.075 
Post-PCB dissection 3 (1.4) 2 (4.7) 1 (0.6) 0.046 
Procedural success 207 (98.6) 2 (4.7) 1 (0.6) 0.046 
Additional stenting 6 (2.9) 2 (4.7) 4 (2.4) 0.428 
Multivessel PCI 28 (13.3) 5 (11.6) 23 (13.8) 0.712 
Values are mean ± SD or n (%). 
PCI= percutaneous coronary intervention; PCB= paclitaxel-coated balloon. Other abbreviations as in 
table 1 and 2. 
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Table 5 Clinical outcomes. 
 
All patients 
(n=206) 
PES-ISR group 
(n=42) 
Non PES-ISR 
group (n=164) 
p-value 
In-hospital events     
   Death 1 (0.5) 0 (0.0) 1 (0.6) 0.612 
   Cardiac death 0 (0.0) 0 (0.0) 0 (0.0) - 
   Myocardial infarction 1 (0.5) 0 (0.0) 1 (0.6) 0.612 
   Target lesion revascularization 2 (1.0) 0 (0.0) 0 (0.0) 0.472 
      PCI 2 (1.0) 0 (0.0) 2 (1.2) 0.472 
      CABG 0 (0.0) 0 (0.0) 0 (0.0) - 
   Target vessel revascularization 9 (4.4) 2 (4.8) 7 (4.3) 0.889 
   Composite MACE 
3 (1.5) 0 (0.0) 3 (1.8) 0.377 
Events at 9 months (n=187) 36 (92.3) 131 (88.5) - 
   Death 5 (2.7) 2 (5.1) 3 (2.0) 0.279 
   Cardiac death 4 (2.1) 1 (2.6) 3 (2.0) 0.837 
   Myocardial infarction 9 (4.8) 2 (5.1) 7 (4.2) 0.918 
   Target lesion revascularization 13 (7.0) 1 (2.6) 12 (8.1) 0.226 
      PCI 11 (5.9) 1 (2.6) 10 (6.8) 0.322 
      CABG 3 (1.6) 0 (0.0) 3 (2.0) 0.370 
   Target vessel revascularization 19 (10.2) 3 (7.7) 16 (10.8) 0.566 
   Composite MACE 20 (10.7) 3 (7.7) 17 (11.5) 0.495 
Values are n (%). 
CABG= coronary artery bypass graft; MACE= major adverse cardiac events. Other abbreviations as in 
table 1 and 3. 
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Table 6 Comparison of pre- and post-procedural MLD, reference vessel diameters, diameter 
stenosis, TLR and MACE rates in PCB groups across studies investigating treatment of DES-
ISR. 
 
GARO 
Registry 
Habara et 
al.11 
PEPCAD 
DES12 
ISAR 
DESIRE 314 
Habara et 
al9 
PEPCAD China 
ISR13 
Pre-procedural 
MLD, mm 
0.98±0.47 0.99±0.32 0.66±0.40 0.97±0.50 0.87 ± 0.40 0.85±0.38 
Post-procedural 
MLD, mm 
2.37 ±0.55 1.99±0.32 2.15±0.42 2.29±0.44 1.87 ± 0.37 2.39±0.37 
Reference vessel 
diameter, mm 
2.78±0.52 2.74±0.34 2.92±2.47 2.75±0.5 2.49 ± 0.50 2.59±0.40 
Post-procedural 
diameter stenosis, 
% 
15.6±12.5 25.7±7.2 12.6±6.2 18.5±8.3 23.6 ± 7.3 10.5±7.2 
TLR, %* 7.0 4.3 15.3 22.1 2.9 14.7 
MACE,%* 10.7 4.3 16.7 23.5 6.6 16.5 
DES= Drug-eluting stent; ISAR-DESIRE 3= Intracoronary Stenting and Angiographic 
Results: Drug Eluting Stents for In-Stent Restenosis 3; MLD=Minimal lumen diameter; PEPCAD-
China ISR= A Prospective, Multicenter, Randomized Trial of Paclitaxel-Coated Balloon versus 
Paclitaxel-Eluting Stent for the Treatment of Drug-eluting Stent In-Stent Restenosis; PEPCAD 
DES=Treatment of DES-In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting PTCA 
Catheter;  TLR=Target lesion revascularization. Other abbreviations as in tables 1, 2, 4 and 5. 
*Time of follow-up was 6 months for Habara et al9,11 and PEPCAD DES12; 9 months for 
PEPCAD China ISR13 and the GARO registry and 12 months for ISAR-DESIRE 314. 
